Neonatology Department, Istanbul Basaksehir Cam and Sakura City Hospital, Basaksehir, Istanbul, Turkey.
Am J Perinatol. 2023 Nov;40(15):1715-1724. doi: 10.1055/s-0041-1740177. Epub 2021 Nov 28.
Novel coronavirus disease 2019 (COVID-19) is a disease associated with atypical pneumonia caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). The first cases of COVID-19 were reported in Wuhan at the end of 2019. Transmission usually occurs via infected droplets and close personal contact; the possibility of vertical transmission is still under debate. This retrospective study aimed to analyze clinical characteristics of premature infants born to mothers with symptomatic COVID-19 disease.
This case control study compared the clinical and laboratory data of 20 premature infants born to mothers infected with SARS-CoV-2 with sex and gestational age-matched historical controls.
The median gestational age and birth weight in both groups were similar. Respiratory distress developed in 11 (55.5%) infants in study group and 19 (47.5%) infants in control group. Mechanical ventilation and endotracheal surfactant administration rates were similar. Median duration of hospitalization was 8.5 (2-76) days in study group and 12 days in historical controls. Real-time reverse-transcription polymerase chain reaction tests (RT-PCR) of nasopharyngeal swab samples for SARS-CoV-2 were found to be negative twice, in the first 24 hours and later at 24 to 48 hours of life. No neutropenia or thrombocytopenia was detected in the study group. Patent ductus arteriosus, bronchopulmonary dysplasia, and necrotizing enterocolitis rates were similar between groups. No mortality was observed in both groups.
To the best of our knowledge, this is one of the few studies evaluating the clinical outcomes of premature infants born to SARS-CoV-2 infected mothers. There was no evidence of vertical transmission of SARS-CoV-2 from symptomatic SARS-CoV-2-infected women to the neonate in our cohort. The neonatal outcomes also seem to be favorable with no mortality in preterm infants.
· SARS-CoV-2 pandemic is a challenge for pregnant women.. · Neonatal outcomes of premature infants born to mothers infected with SARS-CoV-2 not well defined.. · SARS-CoV-2 infection seems to have no adverse effect on mortality and morbidity in premature infants..
2019 年新型冠状病毒病（COVID-19）是一种与由严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的非典型性肺炎相关的疾病。2019 年底，武汉首次报告了 COVID-19 病例。传播通常通过感染飞沫和密切的个人接触发生；垂直传播的可能性仍存在争议。本回顾性研究旨在分析患有症状性 COVID-19 疾病的母亲所生早产儿的临床特征。
本病例对照研究比较了 20 例感染 SARS-CoV-2 的母亲所生早产儿与性别和胎龄匹配的历史对照的临床和实验室数据。
两组的中位胎龄和出生体重相似。研究组 11 例（55.5%）和对照组 19 例（47.5%）婴儿出现呼吸窘迫。机械通气和气管内表面活性剂给药率相似。研究组中位住院时间为 8.5 天（2-76 天），历史对照组为 12 天。对鼻咽拭子样本进行的实时逆转录聚合酶链反应（RT-PCR）检测结果显示，在生命的前 24 小时和 24 至 48 小时内，两次检测 SARS-CoV-2 均为阴性。研究组未发现中性粒细胞减少或血小板减少。两组的动脉导管未闭、支气管肺发育不良和坏死性小肠结肠炎发生率相似。两组均无死亡病例。
据我们所知，这是为数不多的评估 SARS-CoV-2 感染母亲所生早产儿临床结局的研究之一。在我们的队列中，没有证据表明 SARS-CoV-2 从有症状的 SARS-CoV-2 感染女性垂直传播给新生儿。早产儿也没有死亡，似乎没有不良结局。
·SARS-CoV-2 大流行对孕妇构成挑战。·SARS-CoV-2 感染母亲所生早产儿的新生儿结局尚不清楚。·SARS-CoV-2 感染似乎对早产儿的死亡率和发病率没有不良影响。
